Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
Journal of Translational Medicine2018Vol. 16(1), pp. 184–184
Citations Over TimeTop 10% of 2018 papers
Janet Retseck, Alexis Nasr, Yan Lin, Lin Huang, Prateek Mendiratta, Lisa H. Butterfield, Ahmad A. Tarhini
Abstract
Lower Treg levels at baseline are significantly associated with RFS and increased Treg frequency after CTLA4 blockade was only transient. Lower MDSC was also associated with RFS and MDSC levels were further decreased after ipilimumab. Tumor specific effector immune responses are boosted with CTLA4 blockade and tend to be durable. Trial registration ClinicalTrials.gov Identifier: NCT00972933.
Related Papers
- → Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer(2016)34 cited
- → A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade(2023)4 cited
- → Tumor organoid-originated biomarkers predict immune response to PD-1 blockade(2021)7 cited
- → γδ T cells as unconventional targets of checkpoint blockade(2024)1 cited
- → Cellular mechanisms of anti-tumor responses in patients treated with CTLA-4 blockade(2005)